Professor, Medicine-Beth Israel Deaconess Medical Center, Harvard Medical School
Gastroenterology
Dr. Nezam H. Afdhal, MD
|
|
Give Review
Dr. Nezam H. Afdhal is an expert in the field of Gastroenterology. He has 4 awards "Regional Top Doctor", "Meaningful Use Stage 1 Certification", "Super Doctor" and "Fellow (FACG)". Doctor Nezam H. Afdhal, MD is a published doctor. He has 91 publications published. The most current publication "Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score." Nezam Afdhal accepts Medicare payments and is listed with Medicare.gov.
Publications
- Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.
- Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
- Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
- Improvement of health-related quality of life and work productivity in chronic Hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosb...
- Long-term clinical outcomes in cirrhotic chronic Hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5Â years.
- Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis.
- Contemporary Assessment of Hepatic Fibrosis.
- FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice.
- Low likelihood of intracranial hemorrhage in patients with Cirrhosis and altered mental status.
- Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
- Accuracy of Fibroscan, Compared with Histology, in Analysis of Liver Fibrosis in Patients with Hepatitis B or C: A US Multi-center Study.
- Watchful waiting: role of Disease progression on uncertainty and depressive symptoms in patients with chronic Hepatitis C.
- Treatment cessation in noncirrhotic, e-antigen negative chronic Hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
- Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver Disease.
- IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response.
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- Utilization of FibroScan in Clinical Practice.
- The new paradigm of Hepatitis C therapy: integration of oral therapies into best practices.
- Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients with HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy.
- Is 3 the new 1: perspectives on virology, natural history and treatment for Hepatitis C genotype 3.
- FibroScan in the Diagnosis of Hepatitis C Virus Infection.
- Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial.
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with Hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, mult...
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 Hepatitis C infection: a rand...
- A global view of Hepatitis C: Physician knowledge, opinions, and perceived barriers to care.
- Biopsy No More; Changing the Screening and Diagnostic Algorithm for Hepatitis C.
- Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.
- Fibroscan (transient elastography) for the measurement of liver fibrosis.
- Management of nonalcoholic fatty liver Disease: a 60-year-old man with probable nonalcoholic fatty liver Disease: weight reduction, liver biopsy, or both?
- Circulating microparticles as Disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.
- Evaluation of liver lesions.
- Editorial: staging liver fibrosis in Hepatitis C: a challenge for this decade.
- Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic Hepatitis C.
- Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in Cirrhosis.
- Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
- Effects of Anti-Viral Therapy and HCV Clearance on Cerebral Metabolism and Cognition.
- Differences in the Disposition of Silymarin Between Patients with Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis C.
- Genome-wide association study of interferon-related cytopenia in chronic Hepatitis C patients.
- Circulating microRNAs as biomarkers for hepatocellular carcinoma.
- Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for Hepatitis C treatment response.
- Human T cell microparticles circulate in blood of Hepatitis patients and induce fibrolytic activation of hepatic stellate cells.
- Variants in the ITPA gene protect against ribavirin-induced hemolytic Anemia and decrease the need for ribavirin dose reduction.
- Ultrasound-based hepatic elastography: origins, limitations, and applications.
- Health care quality measurement in the care of patients with Cirrhosis.
- Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 Hepatitis C virus.
- Early TIPS to improve survival in acute variceal Bleeding.
- Lith genes and genetic analysis of cholesterol gallstone formation.
- A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic Hepatitis C: ViSER1 results.
- Helicobacter pylori moves through mucus by reducing mucin viscoelasticity.
- Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic Hepatitis C virus infection in United States.
- Clinical decisions. Management of incidental Hepatitis C virus infection.
- EUS-guided liver biopsy: a procedure looking for an indication.
- Validation of Hepascore, compared to simple indices of fibrosis, in US patients with chronic Hepatitis C virus infection.
- Exceeding the limits of liver histology markers.
- Therapeutic strategies for chronic Hepatitis B virus infection in 2008.
- Diagnosis and quantitation of fibrosis.
- Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic Hepatitis C.
- Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver Disease.
- Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic Hepatitis C virus.
- The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver.
- Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic Hepatitis C.
- Rheology of Gastric mucin exhibits a pH-dependent sol-gel transition.
- Progression of fibrosis in advanced chronic Hepatitis C: evaluation by morphometric image analysis.
- The not so good effects of nitric oxide inhibition with methylene blue in Cirrhosis and ascites.
- Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice.
- Iron, HCV, and liver Cancer: hard metal setting the pace?
- Duration of peginterferon therapy in acute Hepatitis C: a randomized trial.
- Overexpression of estrogen receptor alpha increases hepatic cholesterogenesis, leading to Biliary hypersecretion in mice.
- Progression of fibrosis in Hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis.
- Peginterferon alfa-2b therapy in acute Hepatitis C: impact of onset of therapy on sustained virologic response.
- Antiviral therapy for treatment naïve patients with Hepatitis C virus.
- Atomic force microscopy reveals aggregation of Gastric mucin at low pH.
- Use of growth factors with antiviral therapy for chronic Hepatitis C.
- Viscoelastic properties and dynamics of porcine Gastric mucin.
- Management of Hepatitis C virus in special populations: patient and treatment considerations.
- Lack of the Intestinal Muc1 mucin impairs cholesterol uptake and absorption but not fatty acid uptake in Muc1-/- mice.
- Antiviral therapy for treatment naïve patients with Hepatitis C virus.
- Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis?
- Estrogen receptor alpha, but not beta, plays a major role in 17beta-estradiol-induced murine cholesterol Gallstones.
- Evaluation of liver fibrosis: a concise review.
- Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes.
- Role of epoetin alfa in maintaining ribavirin dose.
- Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation.
- Interaction of mucin with cholesterol enriched vesicles: role of mucin structural domains.
- The natural history of Hepatitis C.
- Diagnosing fibrosis in Hepatitis C: is the pendulum swinging from biopsy to blood tests?
- A solid-state NMR study of phospholipid-cholesterol interactions: sphingomyelin-cholesterol binary Systems.
- Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
- Direct costs of care for hepatocellular carcinoma in patients with hepatitis C Cirrhosis.
Schools
Columbia University College Of Physicians and Surgeons
Procedures Preformed
- Anoscopy
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Hemorrhoidectomy or Excision of Anal Tags
- View All
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- Regional Top Doctor
- Meaningful Use Stage 1 Certification
- Super Doctor
- Fellow (FACG)
Education
-
Boston University Medical Center -
Royal College of Surgeons Ireland
Hospital
-
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1508973173 | |
| NPPES Provider LastName | AFDHAL | |
| NPPES Provider FirstName | NEZAM | |
| NPPES Provider ZIPCode | 02215 | |
| NPPES Provider State | MA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 95.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508973173 |
| Last Name Of The Provider | AFDHAL |
| First Name Of The Provider | NEZAM |
| View All |
Similar Doctors
|
|
Dr. Ram Chuttani, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth K. Speliotes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen E. Corey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zhenglun Zhu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilaad G. Kaplan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ahmad W. Alharbi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daryl T. Lau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nitin Gupta, MD |
|
|
Dr. Matthew J. Hamilton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Byron P. Vaughn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Leffler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Thiim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David G. Forcione, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John Leung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashish K. Tiwari, MD |
|
|
Dr. Bonnie A. Ewald, MD
This Doctor is OpenDoctor Recommended.
|